Consequently, optimizing the dosage of STING agonists is crucial in tumor immunotherapy, striking a delicate balance between maximizing therapeutic benefits and preventing T cell apoptosis to enhance cancer treatment outcomes. This evidence concerns the gene STING1 and cancer.